Insider Trading Alert - CFN, SCHW, BSX, HES And FCX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 7, 2014, 95 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $413.92 to $325,011,000.00.

Highlighted Stocks Traded by Insiders:

CareFusion (CFN) - FREE Research Report

Francis Philip L who is Director at CareFusion bought 6,500 shares at $38.61 on Feb. 7, 2014. Following this transaction, the Director owned 42,179 shares meaning that the stake was reduced by 18.22% with the 6,500-share transaction.

The shares most recently traded at $40.02, up $1.41, or 3.52% since the insider transaction. Historical insider transactions for CareFusion go as follows:

  • 4-Week # shares sold: 21,496
  • 12-Week # shares sold: 83,996
  • 24-Week # shares sold: 87,746

The average volume for CareFusion has been 1.6 million shares per day over the past 30 days. CareFusion has a market cap of $8.2 billion and is part of the health care sector and health services industry. Shares are down 2.61% year-to-date as of the close of trading on Friday.

CareFusion Corporation, a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, respiratory care, and surveillance and analytics. The company has a P/E ratio of 23.1. Currently there are 5 analysts that rate CareFusion a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFN - FREE

TheStreet Quant Ratings rates CareFusion as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full CareFusion Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Charles Schwab (SCHW) - FREE Research Report

Schwab Charles R who is Chairman at Charles Schwab sold 150,000 shares at $24.25 on Feb. 7, 2014. Following this transaction, the Chairman owned 38.1 million shares meaning that the stake was reduced by 0.39% with the 150,000-share transaction.

The shares most recently traded at $24.67, up $0.42, or 1.71% since the insider transaction. Historical insider transactions for Charles Schwab go as follows:

  • 24-Week # shares bought: 11,000

The average volume for Charles Schwab has been 6.7 million shares per day over the past 30 days. Charles Schwab has a market cap of $31.5 billion and is part of the financial sector and financial services industry. Shares are down 5.38% year-to-date as of the close of trading on Friday.

The Charles Schwab Corporation, through its subsidiaries, provides securities brokerage, banking, money management, and financial advisory services to individuals and institutional clients. The company operates through two segments, Investor Services and Institutional Services. The stock currently has a dividend yield of 0.98%. The company has a P/E ratio of 31.3. Currently there are 3 analysts that rate Charles Schwab a buy, 3 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SCHW - FREE

TheStreet Quant Ratings rates Charles Schwab as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, compelling growth in net income, notable return on equity and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Charles Schwab Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Boston Scientific (BSX) - FREE Research Report

Mario Ernest who is Director at Boston Scientific sold 17,104 shares at $12.80 on Feb. 7, 2014. Following this transaction, the Director owned 347,855 shares meaning that the stake was reduced by 4.69% with the 17,104-share transaction.

The shares most recently traded at $13.01, up $0.21, or 1.61% since the insider transaction. Historical insider transactions for Boston Scientific go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 230,466
  • 24-Week # shares sold: 430,902

The average volume for Boston Scientific has been 11.5 million shares per day over the past 30 days. Boston Scientific has a market cap of $17.1 billion and is part of the health care sector and health services industry. Shares are up 8.98% year-to-date as of the close of trading on Friday.

Boston Scientific Corporation develops, manufactures, and markets medical devices used in various interventional medical specialties worldwide. Currently there are 8 analysts that rate Boston Scientific a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSX - FREE

TheStreet Quant Ratings rates Boston Scientific as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Boston Scientific Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hess (HES) - FREE Research Report

Fishman Eric S. who is Vice President and Treasurer at Hess sold 175 shares at $74.79 on Feb. 7, 2014. Following this transaction, the Vice President and Treasurer owned 7,394 shares meaning that the stake was reduced by 2.31% with the 175-share transaction.

The shares most recently traded at $76.88, up $2.09, or 2.72% since the insider transaction. Historical insider transactions for Hess go as follows:

  • 4-Week # shares sold: 4,894
  • 12-Week # shares bought: 750
  • 12-Week # shares sold: 4,894
  • 24-Week # shares bought: 750
  • 24-Week # shares sold: 6,894

The average volume for Hess has been 2.5 million shares per day over the past 30 days. Hess has a market cap of $25.8 billion and is part of the basic materials sector and energy industry. Shares are down 7.01% year-to-date as of the close of trading on Friday.

Hess Corporation, together with its subsidiaries, operates as an independent energy company worldwide. It operates in two segments, Exploration and Production (E&P), and Marketing and Refining (M&R). The stock currently has a dividend yield of 1.31%. The company has a P/E ratio of 13.8. Currently there are 6 analysts that rate Hess a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HES - FREE

TheStreet Quant Ratings rates Hess as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, compelling growth in net income, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Hess Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Freeport-McMoRan Copper & Gold (FCX) - FREE Research Report

Townsend Frances F who is Director at Freeport-McMoRan Copper & Gold bought 320 shares at $31.50 on Feb. 7, 2014. Following this transaction, the Director owned 4,120 shares meaning that the stake was reduced by 8.42% with the 320-share transaction.

The shares most recently traded at $32.48, up $0.98, or 3.02% since the insider transaction. Historical insider transactions for Freeport-McMoRan Copper & Gold go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 822,500
  • 12-Week # shares bought: 20,000
  • 12-Week # shares sold: 822,500
  • 24-Week # shares bought: 38,900
  • 24-Week # shares sold: 822,500

The average volume for Freeport-McMoRan Copper & Gold has been 10.6 million shares per day over the past 30 days. Freeport-McMoRan Copper & Gold has a market cap of $32.7 billion and is part of the basic materials sector and metals & mining industry. Shares are down 14.28% year-to-date as of the close of trading on Friday.

Freeport-McMoRan Copper & Gold Inc. engages in the exploration of mineral resource properties. The company primarily explores for copper, gold, molybdenum, cobalt, silver, and other metals, such as rhenium and magnetite. The stock currently has a dividend yield of 3.96%. The company has a P/E ratio of 11.9. Currently there are 12 analysts that rate Freeport-McMoRan Copper & Gold a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FCX - FREE

TheStreet Quant Ratings rates Freeport-McMoRan Copper & Gold as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Freeport-McMoRan Copper & Gold Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Dow Falls Sharply, Nasdaq Sinks as Wall Street Weighs Trump's New Trade Threats

Bond Yields to Slide for Rest of Year Amid Trade Turmoil, Morgan Stanley Says

Bond Yields to Slide for Rest of Year Amid Trade Turmoil, Morgan Stanley Says

Video: 2018 Is Actually a Normal Year for Stock Market Volatility

Video: 2018 Is Actually a Normal Year for Stock Market Volatility

3 Fierce Chinese Tech Stocks to Gamble on Right Now

3 Fierce Chinese Tech Stocks to Gamble on Right Now